Recent studies indicate that a rare population of primitive quiescent BCR-ABL þ cells are innately insensitive to imatinib mesylate (IM) and persist after IM therapy of patients with chronic myeloid leukemia (CML). New approaches to the eradication of these cells are therefore likely to be crucial to the development of curative therapies for CML. We have now found that Ara-C, LY294002 (a PI-3 (phosphatidylinositol-3 0 kinase) kinase inhibitor), 17AAG (a heat-shock protein (HSP)-90 antagonist) and lonafarnib (a farnesyltransfease inhibitor) all enhance the toxicity of IM on K562 cells and on the total CD34 þ leukemic cell population from chronic phase CML patients. However, for quiescent CD34 þ leukemic cells, this was achieved only by concomitant exposure of the cells to lonafarnib. Ara-C or LY294002 alone blocked the proliferation of these cells but did not kill them, and Ara-C, LY294002 or 17AAG in combination with IM enhanced the cytostatic effect of IM but did not prevent the subsequent regrowth of the surviving leukemic cells. These studies demonstrate the importance of in vitro testing of novel agents on the subset of primary leukemic cells most likely to determine long-term treatment outcomes in vivo.
Introduction
In recent clinical trials, imatinib mesylate (IM, Glivec s / Gleevec s , Novartis Pharma) has proven to be remarkably effective in reducing the burden of leukemia in patients with chronic myeloid leukemia (CML) in chronic phase, with rates of complete hematological and cytogenetic response (CHR, CCR) far surpassing what has been attained with interferon a. [1] [2] [3] [4] Nevertheless, IM resistance and molecular evidence of persistent disease have raised concern and prompted interest in additional strategies to achieve disease eradication without the need for a stem cell transplant. Gene amplification, 5, 6 point mutations, 6 ,7 overexpression of BCR-ABL 8, 9 and increased drug efflux properties 9, 10 have all been implicated as mechanisms of resistance to IM in BCR-ABL þ cell lines in vitro. In patients, 31 distinct BCR-ABL point mutations associated with clinical resistance have been described to date. 11 These confer variable levels of resistance with the T315I and P-loop mutations appearing the most sinister. 6, 12 Such mutations have been assumed to be of greater clinical relevance in patients with advanced disease. However, some have been detected in new cases of CML who achieved CCR, 13 suggesting that the eventual selective outgrowth of pre-existing mutated clones under IM therapy could become a more widespread problem than currently appreciated. This fear is further supported by the fact that molecular evidence of remission is rare, even in those newly diagnosed cases of CML in whom mutations have not been detected and who achieve rapid CCR in response to IM. 3 The observed persistence of CML cells in IM-treated patients who remain in CCR for extensive periods is difficult to reconcile with any of the observed mechanisms of genetically determined IM resistance. Rather, the recent discovery that primitive CML cells are relatively insensitive to IM provides a more likely explanation for the continued presence of small numbers of leukemic cells in patients given IM therapy. [14] [15] [16] We have demonstrated that, in vitro, quiescent CD34 þ leukemic cells remain viable for 3 days in the presence of concentrations of IM that are 10-fold higher than is achieved in patients' plasma with a 400 mg daily dosing regimen. 14 Bhatia and co-workers likewise concluded that primitive progenitors were unlikely to be eradicated in vivo by IM alone based on the finding that IM suppressed the proliferation of leukemic colony-forming cells (CFCs) and long-term culture-initiating cells (LTC-ICs) without inducing their apoptosis. 15 Subsequently, the same group showed that patients in CCR had residual Ph þ CD34 þ , CFCs and LTC-ICs even though their bone marrow cells had been found to be Ph À by conventional cytogenetics and/or fluorescence in situ hybridization (FISH) analysis. 16 Assuming the average patient has 10 12 CML cells at diagnosis, of which 1% is CD34 þ and 0.5% of these are quiescent, 17,18 it would be estimated that the average patient harbors 5 Â 10 7 quiescent CD34 þ cells. Given the demonstrated insensitivity of these cells to IM in vitro, it is plausible that they would become the dominant persisting population of CML cells after IM treatment. The measured levels of minimal residual disease (MRD) by quantitative reverse transcriptase-PCR would be in accordance with such a prediction.
Only 4% of patients enrolled in the International Randomized Study of Interferon and STI571 (IRIS) study who achieved CCR had BCR-ABL mRNA levels below the limit of detection. 3 Therefore, persistence of BCR-ABL-expressing cells appears to be the rule and not the exception in IM-treated CML patients. To approach this limitation of IM therapy, the introduction of a second agent has been proposed. Many standard chemotherapeutics as well as newer signal transduction inhibitors have been tested for their ability to complement or synergize with IM in preclinical studies. However, most of this work has been carried out in cell lines, both sensitive and resistant to IM. [19] [20] [21] [22] [23] [24] [25] Such screens have allowed numerous candidates to be identified. However, only limited studies of these agents, in various combinations, have been tested on primitive CML cells from patients. The present experiments were designed to address this problem, with the particular goal of determining the predictability of effects on model systems with the effects achievable on primitive leukemic cells from CML patients. The results demonstrate the marked insensitivity of primitive CML cells to several IM combinations tested with respect to elimination of these cells. 
Materials and methods

Drugs and reagents
Primary cell samples
Fresh leukapheresis products from patients with chronic phase CML at or early postdiagnosis prior to any exposure to IM in vivo were enriched for CD34 þ cells (Table 1) by either lineage depletion (StemSep, StemCell Technologies Inc., Vancouver, BC, Canada) or positive selection (Isolex 50, NEXELL International, Brussels, Belgium) and cryopreserved until required. All human cell samples were obtained with informed consent.
Cell culture
The Ph þ blast crisis-derived K562 cell line was maintained in supplemented RPMI 1640 medium and primary CML cells in supplemented Iscove's modified Dulbecco's medium (IMDM þ ) as described previously.
14,17,18 IMDM þ was further supplemented with a five growth factor (5GF) cocktail comprising Flt3-ligand and stem cell factor (100 ng/ml), and IL-3, IL-6 and G-CSF (20 ng/ml). 14, 17, 18 In vitro cell proliferation assay 
Fluorescence in situ hybridization
The proportion of Ph þ cells was determined by FISH as described previously 14 using the LS1 bcr/abl Dual Fusion probe according to the manufacturer's instructions (Vysis-Abbott, Maidenhead, UK). Interphase nuclei were evaluated using a Leitz fluorescence microscope with a triple band-pass filter for DAPI, Spectrum Orange and Spectrum Green.
Flow cytometry
CD34
þ -enriched cells were recovered from liquid nitrogen, washed once in PBS/2% FCS and then stained with 1 mM carboxy-fluorescein diacetate succinimidyl diester (CFSE, Molecular Probes, Eugene, OR, USA) as described in detail previously. To measure the effects on the cell survival, and to resolve any demonstrable antiproliferative effect, the percentage recovery of viable input total CD34 þ cells was calculated for each division undergone in cultures maintained with 5GFs7test compounds (see Figure 1b) . The number of total CD34 þ cells seeded initially in each culture was recorded and total cell number measured again after 3 days of culture. The level of fluorescence used to identify the subset of CD34 þ cells that had not divided during the 3 days in culture was identified from analyses of cells that had been maintained in the presence of added Colcemid s . Populations of cells that had divided once, twice, three times, etc could then be identified as cells with half, a quarter, an þ cells placed in the culture (Figure 1b worked example) . The value obtained when no drug was added was set to 1 in each experiment for each individual's cells tested, and the recovery of undivided CD34 þ cells for each condition within each experiment then normalized to this value. Differences between average responses (n ¼ 8) of cells cultured7test compounds were compared to no drug control using the Student's t-test.
To determine if the undivided (CFSE max ) CD34 þ cells remaining at the end of the 3-day period of exposure to drug could still proliferate, primary total CD34 þ cell-enriched CML cells, after overnight incubation in SFM and 5GFs, were seeded directly into 24-well tissue culture plates (without cell sorting) at 2.5 Â 10 5 viable cells/ml7drugs as indicated. After 3 days, an aliquot was removed to determine the total number of viable cells remaining and the rest of the cells were then washed free of drug and resuspended in fresh SFM plus 5GFs7drugs, and incubated for a further 3 days.
Statistics
Statistical analyses were performed using the Student's t-test.
Results
Cytotoxicity of various drugs on K562 and primary CD34
þ CML cells are similar
In a first set of experiments, we carried out a parallel series of dose-response studies on K562 cells and on CD34 þ leukemic cells isolated from CML patients with chronic phase disease. The purpose of these experiments was to compare the effects of previously identified candidate drugs of interest (ie Ara-C, lonafarnib, 17AAG and LY294002 as well as IM) in these two experimental models using 3 H-thymidine uptake as a common end point of surviving proliferating cells. Typically, Ara-C reduced K562 proliferation to 50% of the untreated control value at 0.05 mM. IM and 17AAG were equipotent in this regard with IC 50 's of approximately 0.3 mM. Lonafarnib inhibited proliferation of K562 to half the control value at 5 mM. LY294002 was least potent in vitro against K562 cells with an IC 50 of 25 mM. These results confirm previously published findings using K562 cells 9, 19, 23, 27, 28 and demonstrate that, except for lonafarnib, K562 cell responses are strongly predictive of effects on primary CD34 þ chronic phase leukemic cells (which showed IC 50 values of 0.3970.21 mM for IM (n ¼
. Similarly, when Ara-C, lonafarnib, 17AAG or LY294002 was added in combination with IM, a cooperative effect on both K562 and total primary CD34 þ CML cells was obtained in each case (Figure 2 ).
Quiescent CD34
þ CML cells are less sensitive than proliferating CD34
þ CML cells to Ara-C, lonafarnib, 17AAG and LY294002
To determine whether the responses of the total CD34 þ leukemic cell population to the drugs tested would be mirrored by the quiescent subset of this population, an experimental design to discriminate effects on their survival and proliferation was used, as described in the Materials and methods. The results are summarized in Table 2 . None of the five agents tested at concentrations corresponding to the IC 50 values for the total CD34 þ CML population decreased the number of CD34 þ CML cells remaining in an undivided state after 3 days in culture. Moreover, Ara-C at 0.05 mM, LY294002 at 25 mM and IM at 0.5 mM all enhanced the number of undivided CD34 þ cells remaining by comparison to the numbers of these present when no drug was added. Further, Ara-C or LY294002 in combination with 0.5 mM IM, and 17AAG or LY294002 in combination with 5 mM IM, resulted in an even greater accumulation of undivided cells than was seen with either agent alone. In contrast, lonafarnib with 5 mM IM gave the opposite effect on quiescent CML cell numbers causing a slight reduction in the number of quiescent CD34
þ CML cells recovered after 3 days of exposure (illustrative profiles shown in Figure 1c) . It is important to note that the high concentration of IM (5 mM) used in vitro to obtain this effect approximates the steady-state peak plasma concentration in vivo at 400 mg once daily dosing 29 and would be anticipated to be clinically relevant assuming dose proportionality, 30 particularly with the higher doses (400 mg twice daily) now commonly in use.
þ CML cells that survive 3 days of combination drug treatment retain their proliferative capacity
We next determined the effect of the same drug treatments on the total cells present at the end of the 3 or 6 days of drug exposure and on the proliferative ability of the undivided CD34 þ CML cells recovered at the end of the first 3 days. The first effects were determined simply by measuring the total number of viable cells present after 3 or 6 days and then normalizing these values to the fold-change in cell number in Targeting the G 0 subset of primitive CML cells HG Jørgensen et al parallel cultures to which no drug was added. The second was assessed by measuring the total number of viable cells present after 6 days in cultures that contained drug for the first 3 days only. The results of these experiments are shown in Figure 3 . After 3 days, the total cell outputs were reduced in all drugtreated cultures relative to the controls (output o1, Po0.01). However, no significant further reduction was seen after another 3 days of treatment. Importantly, when drug-treated cells were incubated for a second 3 days in the absence of drug, the number of cells increased significantly (Po0.05) after initial exposure to either Ara-C alone or Ara-C in combination with IM, and after exposure to 17 AAG, either alone or with IM, a similar trend but less pronounced effect was obtained. These findings point to an effect that allowed rapid re-expansion of the leukemic clone following drug removal. In contrast, with either lonafarnib alone or in combination with IM, the treated cells failed to expand after removal of the drug.
Discussion
CML is recognized to be a hematopoietic stem cell disorder, and previous studies have demonstrated the existence of primitive CML stem cells that can regenerate CML populations in NOD-SCID mice. 17 Furthermore, most patients with CML show MRD after IM therapy. Taken together, these data suggest that primitive CML cells are likely to be most important to the long-term maintenance and eventual relapsed amplification of Targeting the G 0 subset of primitive CML cells HG Jørgensen et al the malignant clone. Accordingly, there is a growing interest in how these cells can be most effectively targeted. BCR-ABL signaling is now increasingly understood, and this provides a rational basis for the selection of agents most likely to act on primitive CML cells. While certain signal transduction inhibitors have been shown to potentiate the cytotoxicity of conventional agents, others induce cell cycle arrest, thus antagonizing the action of agents that require cell cycle progression to elicit a toxic effect. Similarly, inhibition of cellular proliferation with antileukemic agents may protect Ph þ cells from apoptosis induced by IM.
Here, we chose to evaluate the effect on different populations of primary CML cells of various candidate drugs identified from studies of their effects on K562 cells. A geldanamycin analog, 17AAG, that downregulates BCR-ABL protein processing through antagonism of the HSP-90 chaperone molecule, thus rendering CML cells susceptible to apoptosis, was chosen as a potential IM partner. Secondly, two agents acting on pathways downstream of BCR-ABL, that is, the PI-3K inhibitor, LY294002 and the FTI lonafarnib, were also chosen for study. Ara-C was also included as a representative drug known to kill proliferating cells.
Our results showed K562 cells had IC 50 values similar to those published by others, 9, 19, 23, 27, 28 and that these were similar to the IC 50 values obtained using the total population of CD34 þ CML cells as targets. The exception worth noting was the insensitivity of K562 to lonafarnib (mean IC 50 ¼ 5 mM) relative to total CD34 þ cells (IC 50 ¼ 1.34 mM), which is consistent with the p53 null status of the cell line, 31 and expression of the tumor suppressor correlating with response. 32 Next, we determined the effect of the same drug treatments on the total cell output from the input CD34
þ CML cells and on the proliferative ability of the undivided CD34
þ CML cells remaining after 3 days of drug exposure. The latter would determine if cells inhibited from proliferating in the presence of drugs would be able to divide on removal of the inhibitor. We found that a maximal drug-induced inhibition of total cell output from primitive quiescent CML cells stimulated by GFs in vitro was achieved within 3 days. This effect was not enhanced by extending the treatment for another 3 days, and if the drug was removed, cell output was resumed, particularly for Ara-Ccontaining combinations, with 17 AAG alone or in combination with IM showing a similar trend (P ¼ 0.11), consistent with a reversible, drug-induced blockade of quiescent CML cell activation.
However, when the effects of these drugs on the quiescent subset of CD34 þ CML cells were examined, a quite different picture emerged. For all drugs tested alone, the initially quiescent CD34
þ CML cells were selectively spared. Although other agents may have similar or even greater effects, the only one of those tested here that, when combined with IM, displayed a trend towards a drug-induced decrease in the undivided CD34
þ CML cells within 3 days was lonafarnib. Effect of various drugs on the short-term cell output in vitro by CD34 þ CML cells. CD34 þ CML cells were treated with drug(s) either continuously for 3 days (open bars) or 6 days (gray bars), or for 3 days followed by another 3 days in drug-free medium (black bars), and then the total number of viable cells in each culture were counted. Cells from three individual patients were tested ( UPN 11, 12 and 14) ; the results shown are the mean7s.d. IM and lonafarnib were tested at 5 mM, Ara-C at 0.05 mM and 17AAG at 0.625 mM. w Po0.05, ww Po0.01 with respect to day 6 with washout at day 3 (gray vs black bars); P ¼ NS for 3 vs 6 days continuous drug treatment (white vs gray bars). The number of undivided CD34 + cells present after 3 days was determined as described in the Materials and methods. The value obtained when no drug was added was set to 1 in each experiment for each individual patient's cells tested (n ¼ 8), and the recovery of undivided CD34 + cells for each condition was then normalized to this value. *Pp0.05, **Pp0.01 and ***Pp0.001 with respect to the no drug control.
Targeting the G 0 subset of primitive CML cells HG Jørgensen et al Since primitive CML cells exit from the originally quiescent (undivided) compartment either by proliferation or by death, the end result for each drug combination may reflect a contribution from both these effects. By taking the total cell output (Figure 3 ) and the undivided cell recoveries (Table 2 ), it appears that the combination of Ara-C plus IM produces a reversible antiproliferative effect with a late exodus of cells from the undivided subset mainly by delayed activation of their proliferation. Similarly, 17AAG-treated cells displayed a tendency to be able to divide on removal of the drug. In contrast, the effects of the combination of lonafarnib plus IM were not reversible after day 3 as indicated by the inability of the cells to recover/proliferate in the absence of drug. The inability of these cells to proliferate following removal of lonafarnib from the cultures may, in part, be owing to difficulty in washing out the drug from the cells with respect to the other drugs such as Ara-C.
The activity of lonafarnib against primary CML cells is in agreement with previous results obtained on IM-sensitive and IM-resistant CML cell lines showing synergy between IM and lonafarnib in inducing apoptosis. 23, 33 In addition to its main activity as a modulator of the subcellular localization of Ras, 34, 35 lonafarnib has also been demonstrated to be an inhibitor of certain ATP-binding cassette (ABC) transporter molecules including P-glycoprotein 36 and multidrug resistance proteins 1 and 2. 37 The mechanism of drug resistance in primitive, quiescent CML cells is, however, likely to be multifactorial. Nevertheless, limitation of the intracellular concentration of IM by the efflux activity of ABC proteins may have a role, particularly as stem cells are known to express high levels of these transporters 38, 39 and IM is a known substrate of Pglycoprotein (Mountford et al. Blood 2004; 104: 205a; abstract). 40, 41 Therefore, in addition to an inhibitory action on the Ras pathway, lonafarnib may synergize with IM by inhibiting the ability of primitive CML cells to efflux IM, or MDR modulation may act directly in other unknown ways on primitive CML cells.
Conclusion
IM monotherapy does not appear to eliminate the leukemic cells most probably responsible for maintaining the disease and the response of these cells to a variety of drugs is not predicted by studies of BCR-ABL þ cell lines or even bulk CD34 þ leukemic populations obtained from patients. Therefore, evaluation of useful second-generation therapies will require additional knowledge of not only the oncogene responsible for CML but also the cells that are the root cause of the disease, that is, the Ph þ hematopoietic stem cells. Notably, none of the agents tested in this study, either alone or in combination with IM, successfully eradicated all primitive (quiescent) CML cells in vitro. However, as IM with lonafarnib was the combination that most effectively reduced absolute numbers of quiescent CML cells and restricted the proliferative potential of surviving cells after drug removal in vitro, this partnership may be more appropriate to manage leukemic stem/progenitor cells in vivo.
